In our latest blog, Scott Phillips, VP of Real-World Data at Diaceutics, shares insights on the transformative potential of multi-modal data in precision medicine and its critical role in enhancing patient outcomes and treatment strategies.
1. What is multi-modal data, and why is it important in precision medicine?
Multi-modal data addresses the limitations of relying on single data types, which can introduce biases and gaps in a patient’s experience. The foundational purpose of a multi-modal approach is to acknowledge the complexity of a patient’s treatment journey and leverage all available data types. However, simply linking data from various sources is not enough—the real value lies in generating the most actionable and meaningful insights from the data. This is essential for the future of precision medicine. To make the greatest impact and ensure that every patient receives the right treatment, we must strive for more comprehensive and actionable insights.
2. How can lab data be leveraged to improve the adoption of biomarkers and therapies?
At Diaceutics, we begin with lab and genetic data because understanding a patient's biomarker information is critical in precision medicine. However, we also recognize that lab data alone may not capture the full patient journey. By adopting a multi-modal approach, we integrate insights from multiple data sources to provide a more complete picture and drive better decision making.
3. How does a multi-modal approach to data help simplify the complexities of precision medicine?
A simple way to understand the complexity of precision medicine is by considering the question: Who is the right doctor? Patients in precision medicine may see multiple providers, and relying on independent data sources prevents a full understanding of each provider’s role in the patient journey. Ultimately, what matters is ensuring the right patient gets on therapy as quickly as possible. Our multi-modal approach streamlines this process and drives improved outcomes.
4. What are the limitations of traditional claims aggregation, and how does a multi-modal strategy overcome them?
Claims data is primarily used for administrative billing purposes and does not necessarily reflect the true patient experience. It only captures what physicians bill for and what successfully makes it through clearing houses, payers, data processors, and aggregators, leaving many gaps. There are multiple points of failure in this process, and while claims data may show some aspects of the "what," it often lacks the "why" behind a patient’s experience. A multi-modal approach helps uncover these missing insights by integrating multiple data sources.
5. How can pharma and biotech companies use multi-modal data to enhance their commercialization strategies?
Success is not just about having different types of data—it’s about working with a partner who understands the nuances of the data, including biases, gaps, strengths, and weaknesses. Combining multi-modal data with data science, AI, and clinical expertise is the most effective way to maximize commercialization success.
6. What are some examples of multi-modal data driving better patient outcomes?
In our data, we sometimes see claims indicating that a patient has lung cancer. However, when reviewing their lab and EMR data, we find that the patient does not actually have lung cancer. Conversely, we also see cases where a patient has no claims for lung cancer, yet other data sources confirm that they do—and even specify that it is a genetically relevant form of lung cancer. In a single-source data world, these patients would be overlooked, missing critical opportunities to engage with physicians and drive better outcomes. This is unacceptable. Every patient deserves the best chance to receive the most effective therapy.
Discover more in our next webinar
Don’t miss our webinar on Monday, March 10 from 12-1 PM EDT / 5-6 PM CET, where Scott Phillips will discuss these insights further, exploring how leveraging lab and genetic data can overcome the limitations of traditional claims aggregation, improve physician engagement, and accelerate patient access to treatment. This webinar will also feature a live Q&A session, providing an exclusive opportunity to ask your questions and gain direct insights from an industry expert.
Find out more and register for webinar here
